A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
A Randomized, Double-blind, Placebo-controlled of GR2303 Injection in Healthy Adult Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacologic of GR2303
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
64 participants
Sep 18, 2025
INTERVENTIONAL
Conditions
Summary
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups
Eligibility
Inclusion Criteria2
- Healthy adult subjects
- Signed informed consent
Exclusion Criteria4
- History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
- Prior use of drug targeting TNF-like cytokine 1A
- history of malignant tumor
- psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
single dose
single dose
multiple dose
multiple dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07199270